Indian CROs may feel the heat after local firm, Axis, is suspended
This article was originally published in Scrip
India is set investigate the working of bio-availability and bio-equivalence study centres in the southern state of Andhra Pradesh, after a recent inquiry revealed significant irregularities in a study on the anticancer, exemestane, conducted by the clinical research organization(CRO), Axis Clinicals, there.
You may also be interested in...
Gilead clarifies position on Cipla’s sub-licensing effort for remdesivir, the investigational antiviral in the global spotlight as a potential treatment for COVID-19.
Sun Pharma says that the first quarter of financial 2021 will likely be challenging across the industry with a lull in new prescriptions in India, especially in the acute and semi-chronic segments. But the firm remains upbeat about its lead psoriasis asset Ilumya, which has inched close to the $100m sales mark in its first full year of commercialization.
Physicians may have new expectations from pharma sales reps in India amid COVID-19 and teleconsulting efforts will likely see a significant uptick, at least until the pandemic plateaus, a new survey finds.